Press coverage about Aclaris Therapeutics (NASDAQ:ACRS) has trended somewhat positive on Saturday, according to Accern. Accern rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aclaris Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 47.0510158956239 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
A number of research firms have recently issued reports on ACRS. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Aclaris Therapeutics in a research report on Tuesday. Zacks Investment Research cut Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. ValuEngine cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 12th. JMP Securities reiterated an “outperform” rating and set a $39.00 target price on shares of Aclaris Therapeutics in a research note on Friday, September 8th. Finally, BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $39.20.
Shares of Aclaris Therapeutics (NASDAQ ACRS) traded up $1.19 during midday trading on Friday, hitting $23.23. The stock had a trading volume of 133,800 shares, compared to its average volume of 272,019. Aclaris Therapeutics has a one year low of $20.20 and a one year high of $33.25.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.23. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $2.00 million. research analysts expect that Aclaris Therapeutics will post -2.73 EPS for the current year.
In related news, Director Andrew N. Schiff acquired 108,601 shares of the stock in a transaction on Wednesday, August 16th. The shares were purchased at an average price of $23.02 per share, for a total transaction of $2,499,995.02. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 16.30% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Aclaris Therapeutics (ACRS) Share Price” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/11/11/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-aclaris-therapeutics-acrs-share-price.html.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.